AGI's quantitative imaging services extend beyond data collection to include advanced computational analysis, customized reporting formats, and regulatory-ready outputs. Using proprietary segmentation tools, volumetric assessments, and three-dimensional reconstructions, we provide precise measurements of tissue morphology, biomarker expression, and therapeutic impact across MRI, CT, PET, and histological datasets. These analyses generate reproducible, metric-driven results that enhance interpretability and support regulatory filings for IND and CTA submissions. Reports are tailored to align with sponsor protocols, incorporating both standardized endpoints and customized metrics specific to the therapeutic under evaluation.

 

Integration with clinical pathology, biomarker panels, and pharmacokinetics ensures that imaging results are contextualized within the broader biological response, strengthening translational relevance. Real-time dashboards and interim data releases provide sponsors with early access to key findings, facilitating adaptive trial design and efficient decision-making. All outputs are validated for reproducibility and prepared to meet global submission standards, ensuring seamless integration into the regulatory review process. By merging advanced image analytics with sponsor-specific needs, we enable high-quality, actionable insights that accelerate therapeutic evaluation and reduce development risk.